Evotec SE
Research Evotec SE (EVO) on Bullrun: market cap USD 671.29M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerEVO
- ExchangeNASDAQ
- CountryGermany
- SectorHealthcare
- IndustryDrug Manufacturers-Specialty & Generic
- CurrencyUSD
- Market capUSD 671.29M
- Financial periodQ1 2026
- RevenueEUR 156.64M
- Net income-EUR 121.94M
- Free cash flow-EUR 14.70M
- Gross margin-1.0%
Valuation Snapshot
latest market cap is USD 671.29M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 788.37M | -EUR 103.52M | -EUR 91.80M | 14.5% | -0.62 | EUR 401.79M | EUR 447.69M | EUR 813.70M |
| FY2024 | EUR 796.97M | -EUR 196.08M | -EUR 114.02M | 14.4% | -1 | EUR 293.46M | EUR 443.54M | EUR 952.53M |
| FY2023 | n/a | n/a | n/a | n/a | -0.43 | EUR 510.91M | EUR 626.21M | EUR 1.12B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 671.29M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.09B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.48B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.16B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 2.86B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 8.39B | 30.1 | n/a | n/a |
About Evotec SE
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Evotec SE's market cap?
Evotec SE's market capitalization is USD 671.29M.
What does Evotec SE do?
Evotec SE operates as a drug discovery and development company in the United States, Germany, France, the United Kingdom, Switzerland, and internationally. It operates in two segments, Shared R&D and Just Evotec Biologics. The company is developing pharmaceutical products in various therapeutic areas, such as oncology, autoimmune, cancer, diabetes, heart failure, immunology, pain and inflammation, infectious, kidney, liver, respiratory, fibrotic and metabolic diseases, and rare diseases.